| Property |
Value |
| Pathway |
PANoptosis |
| Full Name |
Pyroptosis-Apoptosis-Necroptosis |
| Key Proteins |
ZBP1, NLRP3, ASC, CASP1, CASP8, RIPK1, RIPK3, MLKL |
| Cell Death Type |
Programmed cell death (hybrid) |
| Discovery |
2016 (Karki et al.) |
PANoptosis (Pyroptosis-Apoptosis) is a unique programmed cell death pathway that involves the coordinated activation of pyroptosis, apoptosis, and necroptosis. Unlike traditional cell death pathways that operate independently, PANoptosis represents an interconnected inflammatory cell death program that cannot be classified into any single cell death category. This hybrid cell death pathway has emerged as a critical mechanism in neurodegenerative diseases, where it contributes to neuronal loss and disease progression.
The PANoptosome is a large multiprotein complex that serves as the central hub for PANoptosis activation:
flowchart TD
A["ZBP1<br/>Z-DNA Binding Protein 1"] --> BPANoptosome C["omplex"]
C["NLRP3"](/proteins/NLRP3) --> B
D["ASC<br/>PYCARD"] --> B
E["RIPK1"](/genes/ripk1) --> B
F["RIPK3"](/genes/ripk3) --> B
B --> G["Caspace-1"]
B --> H["Caspace-8"]
B --> I["Caspace-3/7"]
G --> J["Pyroptosis<br/>Gasdermin D"]
H --> K["Apoptosis<br/>Caspase-3/7"]
I --> K
B --> L["Necroptosis<br/>ML KL"]
J --> MInflammatory C["ell Death"]
K --> M
L --> M
¶ Sensors and Initiators
- ZBP1 (Z-DNA binding protein 1): Intracellular Z-nucleic acid sensor that recognizes viral RNA and endogenous retroelements
- NLRP3 (NLR family pyrin domain containing 3): Inflammasome component that detects cellular stress and damage signals
- AIM2 (Absent in melanoma 2): DNA sensor that activates inflammasome in response to cytosolic DNA
- ASC (PYCARD): Adaptor protein linking sensor activation to caspase-1
- FADD: Adaptor for death receptor signaling to caspase-8
- Caspase-1: Master regulator of pyroptosis; processes pro-IL-1β, pro-IL-18, and gasdermin D
- Caspase-8: Key mediator of extrinsic apoptosis and regulator of necroptosis
- Caspase-3/7: Executioner caspases of apoptosis
- RIPK1 (Receptor-interacting protein kinase 1): Upstream kinase regulating both apoptosis and necroptosis
- RIPK3: Key mediator of necroptosis; phosphorylates MLKL
- MLKL (Mixed lineage kinase domain-like): Executioner of necroptosis; forms pores in plasma membrane
PANoptosis can be triggered by multiple stimuli:
- Viral infections: ZBP1 recognizes viral RNA genomes (influenza, HSV)
- Mitochondrial dysfunction: mtDNA release activates ZBP1 and NLRP3
- Tau pathology: Hyperphosphorylated tau aggregates trigger inflammasome activation
- Alpha-synuclein: Pathological α-synuclein activates NLRP3 inflammasome
- Oxidative stress: ROS production activates multiple PANoptosis pathways
- TLR activation: Toll-like receptor stimulation provides priming signal
PANoptosis contributes to AD pathogenesis through multiple mechanisms:
- Neuronal loss: PANoptotic cell death drives progressive neuronal demise
- Microglial activation: Inflammasome activation in microglia amplifies neuroinflammation
- Amyloid pathology: Aβ aggregates trigger PANoptosome formation
- Tau pathology: NFT formation correlates with PANoptosis markers
- Blood-brain barrier damage: Endothelial PANoptosis compromises BBB integrity
In PD, PANoptosis affects dopaminergic neurons:
- α-Synuclein toxicity: Pathological α-synuclein activates NLRP3
- Mitochondrial dysfunction: PINK1/Parkin pathway disruption triggers PANoptosis
- Microglial inflammation: Sustained inflammasome activation creates neurotoxic environment
- Dopaminergic neuron loss: PANoptotic cell death contributes to substantia nigra degeneration
PANoptosis mechanisms in ALS:
- Motor neuron death: PANoptotic pathways mediate motor neuron degeneration
- Glial cell involvement: Astrocyte and microglia PANoptosis contributes to disease
- Protein aggregation: TDP-43 and SOD1 aggregates trigger inflammasome activation
- Excitotoxicity: Glutamate toxicity potentiates PANoptosis signaling
FTD involves PANoptosis through:
- TDP-43 pathology: Mislocalized TDP-43 activates ZBP1 pathways
- Neuronal vulnerability: Specific neuronal populations show PANoptosis susceptibility
- Inflammatory responses: Chronic neuroinflammation drives PANoptotic cell death
In HD, PANoptosis contributes to:
- Mutant huntingtin toxicity: mHTT aggregates activate inflammasome pathways
- Energy dysfunction: Mitochondrial impairment triggers PANoptosis
- Striatal neuron loss: Medium spiny neurons particularly vulnerable
- MCC950: Potent NLRP3 inhibitor; blocks PANoptosis initiation
- Dapansutrile (OLT1177): Oral NLRP3 inhibitor in clinical trials
- Dimethyl fumarate: Nrf2 activator with inflammasome-modulating effects
- Emricasan: Pan-caspase inhibitor; blocks apoptosis and pyroptosis
- Z-VAD-FMK: Broad-spectrum caspase inhibitor
- Necrostatin-1: RIPK1 inhibitor; blocks necroptosis pathway
- GSK'872: RIPK3 inhibitor; prevents MLKL activation
- Sorafenib: Multi-kinase inhibitor with necroptosis-modulating activity
- Curcumin: Modulates NLRP3 inflammasome and provides antioxidant effects
- Resveratrol: SIRT1 activator with anti-PANoptotic properties
- Quercetin: Flavonoid with inflammasome-inhibiting effects
- Sulforaphane: Nrf2 activator; reduces oxidative stress-triggered PANoptosis
Several trials are investigating PANoptosis-targeted therapies:
| Compound |
Target |
Phase |
Condition |
| Dapansutrile |
NLRP3 |
Phase 2 |
Osteoarthritis, COVID-19 |
| Dimethyl fumarate |
NLRP3/Nrf2 |
Phase 3 |
MS, ALS |
| Emricasan |
Caspases |
Phase 2 |
Liver disease |
- NLRP3 inhibitor + caspase inhibitor: Dual targeting of pyroptosis and apoptosis
- RIPK1 inhibitor + antioxidants: Combined necroptosis blocking and oxidative stress reduction
- Anti-inflammatory + neuroprotective: Addressing both cell death and neuroprotection
PANoptosis connects to multiple existing wiki pathways:
- Circulating PANoptosis markers: IL-1β, IL-18, MLKL phosphorylation
- Genetic variants: NLRP3, ZBP1, RIPK1 polymorphisms associated with disease risk
- Gene therapy: AAV-delivered PANoptosis inhibitors
- Small molecule development: More potent and selective inhibitors
- Cell-permeant peptides: Blocking PANoptosome assembly
- Immunomodulation: Targeting microglial PANoptosis
Recent research on panoptosis in neurodegeneration: